Table 2 Patient characteristics at baseline and response to treatment.
| Variable | SVR (n = 79) | NR (n = 58) | p Value |
|---|---|---|---|
| Age (y) | 40.9 (9.9) | 43.3 (9.3) | 0.84 |
| Sex | |||
| Male | 44 (57.1%) | 33 (42.9%) | 0.15 |
| Female | 35 (58.3%) | 25 (41.7%) | |
| ALT (U/l) | 122.5 (73.2) | 110.5 (92.6) | 0.78 |
| HCV genotype | |||
| 1 | 52 (50.5%) | 51(49.5%) | 0.003 |
| Non‐1 | 27 (79.4%) | 7 (20.6%) | |
| HCV viral load | |||
| Low (<5×105 IU/ml) | 40 (76.9%) | 12 (23.1%) | 0.01 |
| High (⩾5×105 IU/ml) | 39 (45.9%) | 46 (54.1%) | |
| Grade score (Ishak) | |||
| 0–6 | 43 (55.1%) | 35 (44.9%) | 0.46 |
| 7–14 | 36 (61.1%) | 23 (38.9%) | |
| Stage score (Ishak) | |||
| 0–3 | 64 (60.4%) | 42 (39.6%) | 0.11 |
| 4–6 | 15 (48.4%) | 16 (51.6%) | |
| Serum IP‐10 (pg/ml) | 332.4 (222.1) | 476.8 (305.3) | 0.004 |
SVR, sustained virological responders; NR, non‐responders; ALT, alanine aminotransferase; HCV, hepatitis C virus; IP‐10, interferon γ inducible protein 10.
Data are n (%) or mean (SD).